<DOC>
	<DOCNO>NCT00002730</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Some tumor become resistant chemotherapy drug . Combining buthionine sulfoximine chemotherapy may reduce resistance drug allow tumor cell kill . PURPOSE : Phase I trial study effectiveness melphalan , buthionine sulfoximine , G-CSF treat child progressive neuroblastoma respond previous therapy .</brief_summary>
	<brief_title>Chemotherapy Treating Children With Neuroblastoma</brief_title>
	<detailed_description>OBJECTIVES : I . Describe toxic effect combine chemotherapy buthionine sulfoximine ( BSO ) melphalan ( L-PAM ) pediatric patient progressive neuroblastoma . II . Determine pharmacokinetics BSO/L-PAM pediatric patient . III . Assess ability BSO deplete glutathione least 90 % tumor metastatic bone marrow , normal marrow , peripheral blood lymphocyte . IV . Estimate response rate patient treat BSO/L-PAM within confines pilot study . OUTLINE : The follow acronym use : BSO Buthionine sulfoximine , NSC-326231 L-PAM Melphalan , NSC-8806 G-CSF Granulocyte Colony-Stimulating Factor , NSC-614629 Single-Agent Chemotherapy Drug Resistance Inhibition . L-PAM/BSO . PROJECTED ACCRUAL : At least 18 patient enter provide adequate number patient marrow involvement ; BSO dose increase achieve adequate GSH depletion marrow , additional 12 patient enter . If less 50 % patient tumor metastatic marrow entry , proportional increase total number patient require .</detailed_description>
	<mesh_term>Neuroblastoma</mesh_term>
	<mesh_term>Melphalan</mesh_term>
	<mesh_term>Buthionine Sulfoximine</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Neuroblastoma histologically confirm initial diagnosis demonstration malignant , small , round cell tumor elevate catecholamine metabolite Refractory conventional therapy high priority therapy PATIENT CHARACTERISTICS : Age : No great 21 diagnosis Performance status : 02 Life expectancy : At least 2 month Hematopoietic : Cytopenias marrow involvement eligible study chairman approval ANC least 1,000 Platelets least 100,000 ( transfusion independent ) Counts 70,000100,000 allow provide : Autologous bone marrow peripheral stem cell available rescue Study chairman approve entry Hemoglobin least 8 g/dL ( may transfuse ) Hepatic : Bilirubin great 1.5 time normal AST/ALT le 2.5 time normal Renal : Creatinine great 1.5 time normal OR Creatinine clearance radioisotope GFR least 70 mL/min per 1.73 square meter Pulmonary : No history dyspnea rest No exercise intolerance Other : No active infection require hospitalization No pregnant nursing woman Negative pregnancy test require fertile woman Effective contraception require fertile patient 2 month study Patients unable receive blood product due religious reason may receive buthionine sulfoximine alone PRIOR CONCURRENT THERAPY : At least 6 month since myeloablative therapy bone marrow transplantation Recovered toxic effect prior therapy Biologic therapy : Not specify Chemotherapy : At least 3 week since chemotherapy ( 6 week since mitomycin nitrosourea ) Endocrine therapy : Not specify Radiotherapy : At least 6 week since radiotherapy extremity site significant marrowcontaining compartment At least 6 month since follow : More 24 Gy craniospinal irradiation Total abdominopelvic plus lung irradiation Mantle plus Yport irradiation Totalbody irradiation No palliative radiotherapy bony lesion within 1 month entry Surgery : Not specify</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>21 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>recurrent neuroblastoma</keyword>
</DOC>